Literature DB >> 18443639

Effectiveness of opioids in the treatment of chronic non-cancer pain.

Andrea M Trescot1, Scott E Glaser, Hans Hansen, Ramsin Benyamin, Samir Patel, Laxmaiah Manchikanti.   

Abstract

For thousands of years, opioids have been used to treat pain, and they continue to be one of the most commonly prescribed medications for pain. It is estimated that 90% of patients presenting to pain centers and receiving treatment in such facilities are on opioids. Opioids can be considered broad-spectrum analgesics that act at multiple points along the pain pathway. Unfortunately, opioids also have the potential for great harm, with multiple side effects and potential complications, some of which are lethal. They are also uniquely addictive, which can lead to misuse and diversion. We reviewed the relevant English literature and did thorough manual searches of the bibliographies of known primary and review articles. We utilized pain relief as the primary outcome measure. Other outcome measures were functional improvement, improvement of psychological status, improvement in work status, and evidence of addiction. Short-term use and improvement was defined as less than 6 months and long-term relief was defined as 6 months or longer. The 3 systematic reviews evaluating long-term effectiveness of opioids for chronic non-cancer pain provided unclear and weak evidence. The results of this review showed that many patients in the included studies were dissatisfied with adverse events or insufficient pain relief from opioids and withdrew from the studies. For patients able to continue on opioids, evidence was weak suggesting that their pain scores were lower than before therapy and that this relief could be maintained long-term (> 6 months). There was also weak evidence that long-term opioid therapy with morphine and transdermal fentanyl not only decreases pain but also improves functioning. Limited evidence was available for the most commonly used opioids, oxycodone and hydrocodone. Evidence for the ability to drive on chronic opioid therapy was moderate without major side effects or complications. It is concluded that, for long-term opioid therapy of 6 months or longer in managing chronic non-cancer pain, with improvement in function and reduction in pain, there is weak evidence for morphine and transdermal fentanyl. However, there is limited or lack of evidence for all other controlled substances, including the most commonly used drugs, oxycodone and hydrocodone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443639

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  46 in total

1.  Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain.

Authors:  Yin Wan; Shelby Corman; Xin Gao; Sizhu Liu; Haridarshan Patel; Reema Mody
Journal:  Am Health Drug Benefits       Date:  2015-04

2.  Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids.

Authors:  Shiva K Ratuapli; Michael D Crowell; John K DiBaise; Marcelo F Vela; Francisco C Ramirez; George E Burdick; Brian E Lacy; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 3.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

4.  Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature.

Authors:  Mahsa M Yazdy; Rishi J Desai; Susan B Brogly
Journal:  J Pediatr Genet       Date:  2015-04-01

5.  Public Health Detailing-A Successful Strategy to Promote Judicious Opioid Analgesic Prescribing.

Authors:  Jessica A Kattan; Ellenie Tuazon; Denise Paone; Deborah Dowell; Linda Vo; Joanna L Starrels; Christopher M Jones; Hillary V Kunins
Journal:  Am J Public Health       Date:  2016-08       Impact factor: 9.308

6.  Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain.

Authors:  Ancilla W Fernandes; David M Kern; Catherine Datto; Yen-Wen Chen; Charles McLeskey; Ozgur Tunceli
Journal:  Am Health Drug Benefits       Date:  2016-05

7.  Analysis of inflammation-induced depression of home cage wheel running in rats reveals the difference between opioid antinociception and restoration of function.

Authors:  Ram Kandasamy; Jonas J Calsbeek; Michael M Morgan
Journal:  Behav Brain Res       Date:  2016-10-13       Impact factor: 3.332

Review 8.  Adverse effects of chronic opioid therapy for chronic musculoskeletal pain.

Authors:  Leslie J Crofford
Journal:  Nat Rev Rheumatol       Date:  2010-04       Impact factor: 20.543

9.  Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.

Authors:  Marc Afilalo; Mila S Etropolski; Brigitte Kuperwasser; Kathy Kelly; Akiko Okamoto; Ilse Van Hove; Achim Steup; Bernd Lange; Christine Rauschkolb; Juergen Haeussler
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

10.  Bidirectional effects of fentanyl on dendritic spines and AMPA receptors depend upon the internalization of mu opioid receptors.

Authors:  Hang Lin; Paul Higgins; Horace H Loh; Ping-Yee Law; Dezhi Liao
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.